Jeanine Jarnes, PharmD, BCOP, BCPS

Assistant Professor, Department of Pediatrics

Fellowship in the Lysosomal Disease Network, University of Minnesota, Minneapolis, MN

PharmD, University of Minnesota College of Pharmacy, Minneapolis, MN

MSc in Pharmacogenetics, Manchester University, Indianapolis, IN

Certificate Program in Genetics and Genomics, Stanford University, Palo Alto, CA

Certification in Pharmaceutical Care Practitioner, University of Minnesota College of Pharmacy

Summary

Jeanine Jarnes, PharmD, is an Assistant Professor in the University of Minnesota Department of Pediatrics and is an adjunct assistant professor in the College of Pharmacy, University of Minnesota. Jeanine is a board certified Pharmacotherapy Specialist, as well as having a board certification in oncology pharmacy. Jeanine works as a pharmacotherapy provider for patients with inherited metabolic diseases at the University of Minnesota Specialty Clinics. She also serves as a Clinical Pharamcogeneticist for the Lysosomal Disease Network and as a clinical researcher for patients with lysosomal diseases. Dr. Jarnes’s research includes projects in the following areas: natural history of gangliosidosis diseases, such as Tay-Sachs disease, Sandhoff disease, and GM1-gangliosidosis, using a substrate reducing therapy protocol for treatment of childhood gangliosidosis diseases, classifying and managing infusion reactions to intravenous enzyme replacement therapies for lysosomal diseases, and pharmacokinetics and pharmacodynamics of ERT and of small molecule therapies.

Research

Research Summary/Interests

  • Longitudinal study of the gangliosidosis diseases and development of new treatment therapies.
  • Pharmacogenetics, pharmacodynamics, and pharmacokinetics of enzyme replacement therapies and small molecule therapies for lysosomal diseases and phenylketonuria (PKU).
  • Combination therapies for lysosomal diseases, including Tay-Sachs disease, Gaucher disease, and MPS diseases.
  • Optimizing management of acute, delayed, and biphasic infusion reactions to intravenous enzyme replacement therapy for lysosomal diseases.
  • Pharmaceutical care impact on clinical outcomes in lysosomal diseases and phenylketonuria (PKU).
  • Lysosomotropic agents and their impact on lysosomal diseases.

Clinical

Board Certifications

  • Board of Pharmacy Specialties- Pharmacotherapy
  • Board of Pharmacy Specialties- Oncology Pharmacy
  • Board Certified Registered Pharmacist, State of Minnesota